AlphaCore Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

AlphaCore Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.17M	Sell	2,626 -2,254	-46%	-$1.05M	0.03%	349
2025 Q4	$2.21M	Sell	4,880 -375	-7%	-$162K	0.05%	252
2025 Q3	$2.06M	Buy	5,255 +224	+4%	+$93.6K	0.07%	187
2025 Q2	$2.24M	Buy	5,031 +4,052	+414%	+$1.87M	0.09%	177
2025 Q1	$475K	Buy	979 +51	+5%	+$23.8K	0.04%	278
2024 Q4	$374K	Sell	928 -22	-2%	-$10.2K	0.08%	148
2024 Q3	$442K	Buy	950 +2	+0.2%	+$961	0.1%	121
2024 Q2	$444K	Buy	+948	New	+$411K	0.11%	114

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AlphaCore Capital's VRTX Position: Q1 2026 in Review

AlphaCore Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 46% in Q1 2026, selling an estimated $1.05M and leaving 2,626 shares worth $1.17M. The position accounts for 0.03% of the portfolio, ranked #349.

AlphaCore Capital first reported a position in VRTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.24M in Q2 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

AlphaCore Capital held 2,626 shares of Vertex Pharmaceuticals worth $1.17M as of Q1 2026.
AlphaCore Capital sold 2,254 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.05M.
Vertex Pharmaceuticals made up 0.03% of AlphaCore Capital's portfolio in Q1 2026, its #349 holding.
AlphaCore Capital first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
AlphaCore Capital's Vertex Pharmaceuticals position peaked at $2.24M in Q2 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on AlphaCore Capital's 13F filing for Q1 2026, filed 15 May 2026.